CytoDyn (STU:296) Other Current Payables: €7.93 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:296 CytoDyn Inc STU:296
34 GF Score
Price €0.19
! 1 Warning Sign
View Full Analysis

What is CytoDyn Other Current Payables?

CytoDyn STU:296 -3.03% 34 Other Current Payables is €7.93 Mil as of Feb. 2026. GuruFocus rates STU:296 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

CytoDyn's Other Current Payables for the quarter that ended in Feb. 2026 was €7.93 Mil.

CytoDyn's quarterly Other Current Payables increased from Aug. 2025 (€7.42 Mil) to Nov. 2025 (€7.79 Mil) and increased from Nov. 2025 (€7.79 Mil) to Feb. 2026 (€7.93 Mil).

CytoDyn's annual Other Current Payables increased from May. 2023 (€4.88 Mil) to May. 2024 (€6.28 Mil) and increased from May. 2024 (€6.28 Mil) to May. 2025 (€7.33 Mil).

CytoDyn Other Current Payables Related Terms

CytoDyn Other Current Payables Historical Data

* Premium members only.

The historical data trend for CytoDyn's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Other Current Payables Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.18 3.76 4.88 6.28 7.33

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.58 7.33 7.42 7.79 7.93
STU:296
34GF Score
CytoDyn Inc STU:296
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €7.93 Mil mean?
CytoDyn (STU:296) has a Other Current Payables of €7.93 Mil as of Feb. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on CytoDyn and its competitors.
Is CytoDyn's Other Current Payables too high?
CytoDyn's current Other Current Payables is €7.93 Mil. Overall, CytoDyn has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Other Current Payables compare to VSTM and IRD?
CytoDyn's Other Current Payables of €7.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on CytoDyn and its competitors. CytoDyn's current Other Current Payables is €7.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Other Current Payables of €7.93 Mil. The current Other Current Payables is €7.93 Mil. CytoDyn's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For CytoDyn (STU:296), the current Other Current Payables is €7.93 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
34GF Score

Get the complete analysis for STU:296

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price